Home > Boards > US Listed > Biotechs > Can-Fite BioPharma (CANF)

Can-Fite Reports Receives Notice Of Allowance For Namodenoson

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
swanlinbar Member Profile
 
Followed By 71
Posts 11,381
Boards Moderated 9
Alias Born 08/09/00
160x600 placeholder
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/6/2020 8:09:50 AM
Can-Fite Announces $3.4 Million Registered Direct Offering Business Wire - 7/6/2020 8:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/30/2020 7:08:57 AM
Can-Fite Announces Final Data Analysis from Phase II NASH Study: Business Wire - 6/30/2020 7:00:00 AM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 6/19/2020 4:36:29 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/19/2020 4:24:38 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/19/2020 6:03:47 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/12/2020 8:30:54 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/12/2020 8:04:03 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/10/2020 8:11:22 AM
Can-Fite Announces $8.0 Million Registered Direct Offering Business Wire - 6/10/2020 8:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/9/2020 7:05:20 AM
Following Pre-IND Guidance from FDA Can-Fite to Advance Piclidenoson into Phase II COVID-19 Trial in the U.S. Business Wire - 6/9/2020 7:00:00 AM
Can-Fite Participating in BIO Digital International Convention and One-on-One Partnering Meetings on June 8-12, 2020 Business Wire - 6/8/2020 7:25:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/4/2020 7:22:28 AM
Can-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial & Registration Plan for ... Business Wire - 6/4/2020 7:14:00 AM
Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on June 4th Business Wire - 6/3/2020 7:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 6/1/2020 7:24:12 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/1/2020 7:07:32 AM
Can-Fite Reports First Quarter 2020 Financial Results & Provides Clinical Update Business Wire - 6/1/2020 7:00:00 AM
Can-Fite to Host First Quarter 2020 Financial Results & Clinical Update Conference Call on June 1, 2020 Business Wire - 5/28/2020 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/21/2020 7:13:58 AM
Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent & Trademark Of... Business Wire - 5/21/2020 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/18/2020 7:09:21 AM
Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liv... Business Wire - 5/18/2020 7:00:00 AM
swanlinbar   Thursday, 05/21/20 07:18:53 AM
Re: None
Post # of 1454 
Can-Fite Reports Receives Notice Of Allowance For Namodenoson Patent In Treatment Of NASH, NAFLD From US PTO
7:03 am ET May 21, 2020 (Benzinga) Print
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the U.S. Patent and Trademark Office (PTO) has issued a Notice of Allowance for the Company’s patent titled, “Method for treating NASH accompanied by fibrosis using CI-IB-MECA”. The allowance follows Can-Fite’s recent announcement of highly encouraging data from its Phase II study of its drug candidate Namodenoson, generically known as CI-IB-MECA, in the treatment of non-alcoholic fatty liver disease (NAFLD) with or without non-alcoholic steatohepatitis (NASH).

The allowed patent covers the use of the A3 adenosine receptor (A3AR) in reducing ectopic fat accumulation, particularly in fatty liver. The patent specifically addresses preparation of a pharmaceutical composition for reducing fat accumulation and a method of treating conditions associated with fat accumulation such as fatty liver diseases including NASH and NAFLD.

Can-Fite recently announced findings from its Phase II study of Namodenoson in the treatment of patients with NAFLD with or without NASH. The study achieved its efficacy endpoints in a dose dependent and statistically significant manner, while continuing to demonstrate a good safety profile. The Phase II data revealed that the 25 mg dose of Namodenoson resolved significantly all cases of NASH, representing 25% of the 25 mg treated group, as compared to an increase in new NASH cases in the placebo group from a baseline of 0 to 5.9%. Namodenoson dosed at 25 mg reduced hepatic fibrosis (scar tissue in the liver resulting from the liver trying to repair itself), reduced steatosis (fat buildup in the liver), and improved the FAST score, a measure for NASH (liver stiffness and an enzymatic biomarker of liver damage).

“We are very pleased to receive this Notice of Allowance from the U.S. PTO at this time, immediately following an analysis of Phase II data that show Namodenoson is highly effective in treating and reversing fatty liver. At the optimal 25 mg dosage, Namodenoson eliminated NASH in the Phase II patient population. The protection provided by the allowed patent has a high value for us, as we move forward into advanced stage clinical trials in this indication, and as we evaluate distribution partnerships for Namodenoson,” stated Can-Fite CEO, Dr. Pnina Fishman.

An estimated 85 million Americans have NAFLD, which may lead to an exponential rise in incidence of NASH, a more severe form of NAFLD, to close to 43 million Americans in the next five years. The NASH treatment market is estimated to reach $35-40 billion by 2025.

"that a rich man is not the one who has the most but the one who needs the least"
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist